Jenny Zhou
Education
Ph.D., pharmaceutical economics and policy, M.S., pharmaceutical economics and policy and neuroscience, University of Southern California; Bachelor of Medicine, Shanghai Medical Center, Fudan University
Summary of Experience
Dr. Zhou is a health economist with extensive experience in health economics and outcomes research. Her expertise includes economic evaluation, health technology assessment, and comparative effectiveness research using clinical and real-world evidence. Dr. Zhou has developed evidence submissions – including systematic literature reviews, indirect treatment comparisons, and cost-effectiveness analyses – for health technology appraisals in the UK, EU, and Canada. She also has extensive experience supporting clients through the ICER review process in the US. Dr. Zhou’s additional research has involved evaluating Medicare’s Oncology Care Model (OCM) program; assessing disease burden of illness and treatment patterns; and developing pharmaceutical pricing strategies based on early stage modeling. Her experience encompasses a wide range of therapeutic areas, including oncology and hematology, rare bleeding disorders, genetic diseases, autoimmune diseases, mental health disorders, cardiovascular diseases, and infectious diseases. Dr. Zhou’s work has been published in many peer-reviewed journals and featured at numerous conferences.
-
Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States
Advances in Therapy, 2023
2023Huang M, Fasching PA, Haiderali A, Xue W, Yang C, Pan W, Zhou ZY, Hu P, Chaudhuri M, Le Bailly De Tilleghem C, Cappoen N, O'Shaughnessy J
-
Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
Cancer Medicine, 2023
2023Richter J, Lin PL, Garcia-Horton V, Guyot P, Singh E, Zhou ZY, Sievert M, Taiji R
-
Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer
Immunotherapy, 2022
2022Huang M, Fasching P, Haiderali A, Pan W, Gray E, Zhou ZY, Hu P, Chaudhuri M, Bailly De Tilleghem CL, Cappoen N, O'Shaughnessy J
-
Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a MET exon 14 skipping mutation in the United States
Journal of Medical Economics, 2021
2021Cai B, Zhou ZY, Xue W, Hazra NC, Singh M, Mishra D, Brixner D, Oderda G, Biskupiak J
-
The Risk Reduction of Accidental Exposure-Related Systemic Allergic Reactions Extrapolated Based on Food Challenge Data After 1 Year of Peanut Oral Immunotherapy
Advances in Therapy, 2021
2021Yu S, Smith A, Hass S, Wu E, Chai X, Zhou J, Ayyagari R, Liu JS, Robison D, Donelson SM, Tilles S
-
Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A
Journal of Managed Care & Specialty Pharmacy, 2020
2020Zhou ZY, Raimundo K, Patel A, Han S, Ji Y, Fang H, Zhong J, Betts K, Mahajerin A
-
Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong
Cost Effectiveness and Resource Allocation, 2020
2020Loong HH, Wong CKH, Leung LKS, Chan CPK, Chang A, Zhou ZY, Xie J, Gibbs M
-
Transparency in Health Economic Modeling: Options, Issues and Potential Solutions
PharmacoEconomics, 2019
2019 -
Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States
Journal of Medical Economics, 2019
2019Bensimon AG, Zhou ZY, Jenkins M, Song Y, Gao W, Signorovitch J, Krepler C, Liu FX, Wang J, Aguiar-Ibáñez R
-
Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis
Blood Advances, 2019
2019Ailawadhi S, Parikh K, Abouzaid S, Zhou Z, Tang W, Clancy Z, Cheung C, Zhou ZY, Xie J
-
Indirect costs associated with premature mortality among those with veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan dysfunction post-hematopoietic stem-cell-transplant
ClinicoEconomics and Outcomes Research, 2019
2019Zhou ZY, Tang W, Villa KF
-
Economic Burden of Illness Among Commercially Insured Patients with Systemic Sclerosis with Interstitial Lung Disease in the USA: A Claims Data Analysis
Advances in Therapy, 2019
2019Zhou Z, Fan Y, Thomason D, Tang W, Liu X, Zhou ZY, Macaulay D, Fischer A
-
Economic Burden among Commercially Insured Patients with Systemic Sclerosis in the United States
The Journal of Rheumatology, 2019
2019Zhou Z, Fan Y, Tang W, Liu X, Thomason D, Zhou ZY, Macaulay D, Fischer A
-
Treatment patterns among adults with ADHD receiving long-acting therapy
American Journal of Managed Care. Jul 2018;24(8 Spec No.):SP329-SP337
2018Zhou Z, Zhou ZY, Kellar SS, Sikirica V, Xie J, Grebla R
-
Medication use in adults with attention deficit/hyperactivity disorder in a commercially-insured population in the United States
Current Medical Research and Opinion. Apr 2018;34(4):585-592
2018Zhou Z, Zhou ZY, Kelkar SS, Sikirica V, Xie J, Grebla R
-
Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small-Cell Lung Cancer: A Network Meta-Analysis
Advances in Therapy. 2018 Jul;35(7):1035-1048
2018Li J, Sasane M, Zhao J, García-Horton V, Zhang P, Ricculli ML, Zhou ZY, Signorovitch J
-
Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States
Journal of Medical Economics. Jun 2018;21(6):577-586
2018Zhou ZY, Mutebi A, Han S, Bensimon AG, Louise Ricculli M, Xie J, Dalal A, Culver K
-
Healthcare Resource Use, Costs, and Disease Progression Associated with Diabetic Nephropathy in Adults with Type 2 Diabetes: A Retrospective Observational Study
Diabetes Therapy. Jun 2017;8(3):555-571
2017Zhou Z, Chaudhari P, Yang H, Fang AP, Zhao J, Law EH, Wu EQ, Jiang R, Seifeldin R
-
Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US
Rheumatology and Therapy, 2016 Sep 15
2016Strand V, Husni E, Griffith J, Zhou ZY, Signorovitch J, Ganguli A
-
Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada
Journal of Medical Economics, 2016 05: 1-17. doi: 10.1080/13696998.2016.1187151
2016Hurry M, Zhou ZY, Zhang J, Zhang C, Liangyi F, Rebeira M, Xie J
-
Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis
Advances in Therapy, 2016 05; 33(5): 807-823. e-pub ahead of print 2016/04/17
2016
